Neuropeptides, dopamine, and schizophrenia (Q39548116)

13 September 2017

1 reference

title

Neuropeptides, dopamine, and schizophrenia (English)

1 reference

13 September 2017

1 reference

Nemeroff CB

1

1 reference

13 September 2017

Bissette G

series ordinal

2

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 January 1988

1 reference

Annals of the New York Academy of Sciences

13 September 2017

published in

1 reference

13 September 2017

volume

537

1 reference

13 September 2017

page(s)

273-291

1 reference

Neurotensin: topographical distribution in rat brain by immunohistochemistry

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Regional distribution of neurotensin in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Coexistence of dopamine and neurotensin in hypothalamic arcuate and periventricular neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Biological markers in mental disorders: Post-mortem studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Met-enkephalin level in the cerebrospinal fluid of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Enkephalin-containing polypeptides in human cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

On βH-Leu5-Endorphin and Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Alterations in cerebrospinal fluid concentrations of somatostatinlike immunoreactivity in neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

CSF Somatostatin in Affective Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Reduced cholecystokinin immunoreactivity in the cerebrospinal fluid of patients with psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Delta-sleep inducing peptide in cerebrospinal fluid from schizophrenics, depressives and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Improvement of Schizophrenic Patients Treated With Des-Tyr1]-γ-endorphin (DTγE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Cholecystokinin peptides, dopamine and schizophrenia--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Lack of effect on naloxone on schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Repeated naloxone administration in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

The Effects of Ceruletide in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

Evidence for coexistence of dopamine and CCK in meso-limbic neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1988.TB42113.X

10.1111/J.1749-6632.1988.TB42113.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference